Ninox Medical is developing a new device for the treatment of Obstructive Sleep Apnea (OSA). Obstructive Sleep Apnea syndrome is a disorder characterized by repetitive episodes of upper airway obstruction that occur during sleep. The breathing stops for periods lasting from 10 seconds and up to minutes, followed by stressful arousals during which the patient gasps for air. As a result, oxygen desaturation occurs, inflammatory process may be triggered and lead to the long term cardiovascular or endocrine co-morbidities such as hypertension, ischemic heart disease, stroke and diabetes.
The number of patients suffering from the Obstructive Sleep Apnea is enormous and is growing along with obesity rates. In theUSalone, more than 18 million people have moderate to severe symptomatic condition and are prime candidates for OSA treatment.
NINOX raised additional $10M during the incubation period, from international and Israeli funds. Read more
CEO- Alex Rapoport